With increased regulatory scrutiny, pricing and cost pressures, as well as the rapid developments in genomic technology leading to a more personalised approach to medicine and healthcare, businesses and organisations in the life sciences and healthcare sector face a growing number of complex legal and regulatory challenges in order to stay competitive.
Our International Life Sciences & Healthcare group works with over 50% of the world’s largest pharmaceutical, biotechnology and medical devices companies. We have the largest patent litigation group in Europe and are recognised by major global directories as a top tier life sciences firm.
Our focus on business being changed by technology and the digital world enables us to support our clients operating in this rapidly changing environment. Our multidisciplinary team of 240 specialist life sciences and healthcare lawyers worldwide can advise you on every aspect of the business cycle of a life science and healthcare product or service, from incorporation through development to protection and exploitation of intellectual property.
We can advise you on:
If you would like to know more about how we can help your business, please contact Heads of Group: Marc Martens in Brussels and Mark Hilton in London.
Chambers UK, 2018
Chambers Europe-wide, 2018
Legal 500, 2018
Chambers Asia-Pacific, 2018
Chambers Global- wide, 2018
On 13 June 2019, the Cyberspace Administration of China (CAC) issued a long-awaited second draft Measures on Security Assessment for Export of Personal Information. In this update we examine some of the key takeaways.
The UK Financial Conduct Authority issues its first formal decision under the competition enforcement powers it was given in 2015. We look at the decision in more detail and its implication for market participants.
AIM companies must now disclose details of the recognised corporate governance code that it has adopted, how the company complies with this code or, where it departed from this code, an explanation of the reasons for ...
International law firm Bird & Bird today announces the merger of its Baseline consulting arm with Valeocon Management Consulting, creating one of the largest management consultancy firms linked to an international law ...
International law firm Bird & Bird has advised Chiesi Farmaceutici S.p.A. ("Chiesi") on the in-licence of Raxone® -- an orphan drug used in the treatment of Leber's hereditary optic neuropathy ("LHON")
International law firm Bird & Bird advises the FUJIFILM group on the acquisition of German medwork GmbH, a company that develops, manufactures and markets instruments for therapeutic and diagnostic endoscopy.
There are no forthcoming events for this area. Please click on the button below to view past events.
'Investing in the future of cannabis in the UK - lessons from the German model'. Click here to read article:… https://t.co/9qYy0ULS4J
click here for more info: https://t.co/Wzd1k47smM https://t.co/e6ZmARYxLc
International team advises Chiesi Farmaceutici on in-licence of Raxone® from Santhera. Click here for more informat… https://t.co/BUZD7FhUIA